Many Americans think an HIV/AIDS vaccine already exists

May 19, 2003

Many Americans wrongly believe that a preventive vaccine for HIV/AIDS has already been developed, according to surveys recently conducted by the National Institute of Allergy and Infectious Diseases (NIAID). Nearly half of African Americans surveyed (48 percent) and more than a quarter of Hispanics (28 percent) believe that an HIV vaccine already exists and is being kept a secret. Twenty percent of adults in the general population share that belief.

The preliminary findings are from a national survey of 3,500 people conducted by NIAID, a component of the National Institutes of Health. The research included a 2,000-person national survey of American adults and three smaller surveys of communities most affected by HIV and AIDS (i.e., African American, Hispanics, and men who have sex with men).

As a part of NIAID's efforts to educate the public about ongoing research, the Institute is sponsoring the Sixth Annual HIV Vaccine Awareness Day on May 18. Communities around the country and across the world have planned activities that will provide valuable HIV vaccine information to inform the public and begin to correct misinformation and misperceptions.

"HIV vaccine research is our best hope, along with other prevention and treatment efforts, to slow the spread of HIV," says NIAID Director Anthony S. Fauci, M.D. "NIAID is committed to educating the public to help correct misconceptions and advance public understanding of ongoing and future HIV vaccine research."

The survey found significant support for HIV vaccine research. Eighty-four percent of the public believes that efforts to develop a vaccine to prevent HIV infection are "extremely" or "very" important compared with other medical research needs. Support for HIV vaccine research is even stronger among African-American and Hispanic respondents: 96 six percent of African Americans and 94 percent of Hispanics surveyed believe HIV vaccine research to be "extremely" or "very" important.

Despite that support, the survey indicated some additional, troubling misperceptions about efforts to develop a vaccine to prevent HIV infection. For example, Only 58 percent of those surveyed understand that vaccine development requires testing potential vaccines on thousands of humans before approval.

Nearly one-third mistakenly believe that the HIV vaccines being tested can cause HIV infection in clinical trial volunteers; an additional 44 percent were unsure.

These misperceptions and the lack of substantive knowledge about HIV vaccine research underscore the ongoing need to educate the public about efforts underway to develop a vaccine that prevents HIV infection.

Every day, an estimated 16,000 people worldwide become infected with HIV, according to the Joint United Nations Programme on HIV/AIDS. Approximately 50 percent of the 38.6 million adults living with HIV/AIDS worldwide are women, while 3.2 million are children younger than 15 years old.

In the United States, an estimated 900,000 people are living with HIV. New infections occur at a rate of 40,000 a year; more than half of those new infections occur in people of color. Young people under the age of 25 account for half of all new HIV infections in the United States.

Gary J. Nabel, M.D., Ph.D., director of the Dale and Betty Bumpers Vaccine Research Center in NIAID (, says, "HIV Vaccine Awareness Day provides the public with an opportunity to learn more about HIV vaccine research. Only through research will we be able to meet our ultimate goal and make HIV/AIDS a disease of the past."

Upside-Down Red Ribbon, New Symbol of HIV Vaccine Awareness Day

Nearly 100 organizations throughout the United States will host events to recognize the contributions of thousands of study volunteers, scientists and health professionals working to find a vaccine that prevents HIV infection. This year the day will be commemorated with a twist on a familiar symbol of AIDS awareness. For the first time, organizers are asking people to recognize the promise of HIV vaccine research by wearing a red AIDS ribbon upside-down on HIV Vaccine Awareness Day to form a "V" for "vaccines."

"May 18th provides us with an opportunity to recognize the researchers, community educators and thousands of volunteers around the world who have been involved in the quest for an HIV vaccine," says Margaret (Peggy) I. Johnston, Ph.D., associate director for HIV/AIDS vaccines, NIAID. "HIV continues to spread unabated in many parts of the world. What we need is to stop that spread, and the best hope to do that is through a safe and effective preventive HIV vaccine."

More Vaccine Candidates Than Ever Before in Testing

Discovering a safe, effective vaccine to prevent HIV infection is a research priority for the U.S. government. Funding from NIAID has enabled scientists to put more potential vaccines in the pipelines for testing in the next two years than were tested in the last five years combined.

More than 60 medical research centers around the country have recruited thousands of volunteers to test dozens of potential vaccines. NIAID is currently sponsoring multiple clinical trials of HIV vaccine candidates through the global HIV Vaccine Trials Network (HVTN). These vaccine trials will one day require tens of thousands of additional volunteers. Currently, more than 12,000 men and women worldwide have come forward as volunteers for HIV vaccine research.

More information on HIV vaccine research and HIV Vaccine Awareness Day is available at,, or the HIV Vaccine Trials Network at

HIV Vaccine Awareness Day Events

HIV Vaccine Awareness Day activities will be held throughout the world. This year's events emphasize education and outreach by the research sites, including media events, tours of research facilities, lectures and receptions to honor volunteers. For information about events in specific areas, contact the following:

Baltimore, MD Johns Hopkins University Theron Scott: (410) 614-6619

University of Maryland, Baltimore Sandra Wearins: (410) 706-1290

Bethesda, MD NIAID Vaccine Research Center Nancy Barrett: (301) 435-3676

Birmingham, AL University of Alabama at Birmingham Leslie Cooper: (205) 975-2839

Boston, MA Brigham and Women's Hospital Fenway Community Health Darren LeBlanc: (617) 927-6026 Durban, South Africa Medical Research Center Nobuhle Mkhize: 27-31-203-4700 Gaborone, Botswana Princess Marina Hospital Rupert Hambria: (267) 393-1137 Nashville, TN Vanderbilt University Susan Montgomery: (615) 322-0873 New York, NY Project Achieve/New York Blood Center and Columbia University Denise Goodman: (212) 388-0008 Port-au-Prince, Haiti Cornell-GHESKIO Dr. Mireille Peck: 509-222-00-31 Providence, RI Miriam Hospital Stephanie Howie: (401) 793-4714 Rio de Janiero, Brazil Hospital Escola Sao Francisco de Assis Monica Barbosa: 55-21-2273-9073 Rochester, NY University of Rochester Patrick Fisher: (585) 275-0459 San Francisco, CA San Francisco Department of Public Health Jennifer Sarche: (415) 554-4297 Seattle, WA Fred Hutchinson Cancer Research Center/University of Washington Dennis Torres: (206) 521-5812 Soweto, South Africa Perinatal HIV Research Unit Dr. Glenda Gray: 217-11-989-9703 St. Louis, MO Saint Louis University Kim Dao: (314) 268-5448 Radio Broadcasters: Soundbites are available by calling the NIH Radio News Service at 1-800-MED DIAL (1-800-633-3425). NIAID is a component of the National Institutes of Health (NIH), which is an agency of the Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies. ### Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to